These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30471339)

  • 1. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.
    Jain T; Alahdab F; Firwana B; Sonbol MB; Almader-Douglas D; Palmer J
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):728-733. PubMed ID: 30471339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
    Kawamura K; Kako S; Mizuta S; Ishiyama K; Aoki J; Yano S; Fukuda T; Uchida N; Ozawa Y; Eto T; Iwato K; Kanamori H; Kahata K; Kondo T; Sawa M; Ichinohe T; Atsuta Y; Kanda Y
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2079-2087. PubMed ID: 28890406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
    Shimoni A; Hardan I; Shem-Tov N; Rand A; Herscovici C; Yerushalmi R; Nagler A
    Leukemia; 2007 Oct; 21(10):2109-16. PubMed ID: 17690701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis.
    Yamamoto W; Andou T; Itabashi M; Koyama S; Ishii Y; Numata A; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S
    Intern Med; 2016; 55(13):1721-7. PubMed ID: 27374671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.
    Damlaj M; Alkhateeb HB; Hefazi M; Partain DK; Hashmi S; Gastineau DA; Al-Kali A; Wolf RC; Gangat N; Litzow MR; Hogan WJ; Patnaik MM
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1431-1439. PubMed ID: 27164061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
    Robin M; Porcher R; Wolschke C; Sicre de Fontbrune F; Alchalby H; Christopeit M; Cassinat B; Zabelina T; Peffault de Latour R; Ayuk F; Socié G; Kröger N
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1206-1211. PubMed ID: 26970380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
    Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
    JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
    Alatrash G; Kidwell KM; Thall PF; Di Stasi A; Chen J; Zope M; Crain AK; Champlin RE; Popat U; Shpall EJ; Jones RB; Andersson BS
    Bone Marrow Transplant; 2019 Aug; 54(8):1245-1253. PubMed ID: 30532055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison.
    Beelen DW; Iacobelli S; Koster L; Eikema DJ; van Biezen A; Stölzel F; Ciceri F; Bethge W; Dreger P; Wagner-Drouet EM; Reményi P; Stelljes M; Markiewicz M; McLornan DP; Yakoub-Agha I; Mohty M
    Bone Marrow Transplant; 2024 May; 59(5):670-679. PubMed ID: 38383713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4 Gy TBI versus fludarabine/ busulfan plus 4 Gy TBI.
    Yamada Y; Ikegawa S; Najima Y; Atsuta Y; Konuma R; Adachi H; Wada A; Kishida Y; Konishi T; Nagata A; Kaito S; Nagata R; Noguchi Y; Marumo A; Mukae J; Inamoto K; Toya T; Igarashi A; Kobayashi T; Sakamaki H; Ohashi K; Doki N
    Int J Hematol; 2022 Feb; 115(2):244-254. PubMed ID: 34652634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
    Epperla N; Ahn KW; Armand P; Jaglowski S; Ahmed S; Kenkre VP; Savani B; Jagasia M; Shah NN; Fenske TS; Sureda A; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):78-85. PubMed ID: 29032272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity.
    Chen GL; Hahn T; Wilding GE; Groman A; Hutson A; Zhang Y; Khan U; Liu H; Ross M; Bambach B; Higman M; Neppalli V; Sait S; Block AW; Wallace PK; Singh AK; McCarthy PL
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):689-698. PubMed ID: 30300731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
    Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
    Ciurea SO; Kongtim P; Varma A; Rondon G; Chen J; Srour S; Bashir Q; Alousi A; Mehta R; Oran B; Popat U; Hosing C; Olson A; Daver N; Konopleva M; Champlin RE
    Blood; 2020 Feb; 135(6):449-452. PubMed ID: 31826244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
    Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
    Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.